38 results about "Severe trauma" patented technology

ClotFoam is a surgical sealant and hemostatic agent designed to be used in cases of non-compressible hemorrhage. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade.

The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

The present methods provide access to high flow vessels without causing severe trauma for the patient. At the same time, the methods maximize the size of a vascular instrument that can be deployed at the target location. The methods involve tunneling through the patient's tissue to create an access path between a percutaneous access site and the target location by using a second percutaneous site that is generally subcutaneous.

ClotFoam is an hemostatic agent designed for non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

The invention discloses a severe trauma treatment warning communication system which comprises a vehicle-mounted traumatic condition assessment warning information release terminal, a data center, a first-aid center and a medical first-aid station. The vehicle-mounted terminal comprises a central processing unit (CPU) control module, a man-machine interface module, a high-definition camera, a positing module. The CPU control module transmits collected or reflected information to the data center through a communication system; the data center carries out real-time detection over warning information uploaded by each vehicle-mounted traumatic condition assessment warning information release terminal and uploads the warning information to the first-aid center; the fist-aid center gives out the warning information to the hospital first-aid station. The trauma treatment warning communication system enables an ambulance, a treatment hospital and a specialized treatment team to acquire an early information communication and a warning channel, so that each procedure of treating patients is closely linked together, treatment and waiting time is shortened to an extreme, all procedures for treating and curing the patients can be prepared in advance, and valuable golden rescuing time for curing the severe trauma patients is available.

The transvaginal tactile probe is configured to obtain a high resolution mapping of pressures and strains within the vagina of a pregnant woman prior to birth. The device provides real-time data visualization, analysis tools and information. This data may be used to assist with clinical decisions regarding selecting a preferred method of prevention of severe childbirth injury or altering delivery management, e.g. early induction at term, elective caesarean section in patients with a history of obstetric anal sphincter injury, water-birth, warm compresses to the perineum. The device is intended for use by medically trained personnel who counsels patients regarding risk of severe trauma at childbirth (such as urogynecologists and obstetricians) and regarding the effect of perineal massage and childbirth training device (such as physical therapists).

A composition having modified or derivative of 1,4,6-androstatriene-3,17-dione (“ATD”) will improve the health of mammalian subjects. The improvement of health is achieved with the administration of an effective amount of the at least one modified or derivative of 1,4,6-androstatriene-3,17-dione. Particularly, health is improved for a subject suffering with a gynecomastia, and/or estrogen-dependent cancer. Also, subjects recovering from steroid misuse/abuse with treatment in accordance with the present invention. Other improvements found to occur with an administration of ATD is that growth is enhanced and/or stimulated in developing mammals, recovery is shortened in cases of severe trauma or burns, mood levels are improved, male fertility is improved, and athletic performance is improved by increasing testosterone and lean muscle mass.

A compound of formula (I) or a salt thereof are provided:

wherein R¹, X and R³ are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The composition is a blood clotting composition including at least one hemostatic agent and an indicator agent that adheres to the skin on or around the wound, the indicator agent being specifically identifiable to the hemostatic composition. The composition can be adapted to be applied to a wound as an emergency trauma treatment in homes, public places, trauma treatment centers, at accident locations, in the field of military combat, or any other potential site of severe trauma as a first response to reduce or stop bleeding. The composition can include at least one clotting agent, an analgesic, a bactericide (such as silver), and at least one antibiotic. An applicator device for the composition is included.

The invention relates to an application of a vascular non-inflammatory factor (VNN1) in plasma or serum for markers in early warning of sepsis. According to the application, the VNN1 is adopted as a biomarker, an applicant has verified through experiments that the level of VNN1 in plasma of patients with severe trauma is significantly higher than that of normal people, and the level of VNN1 in plasma of patients with sepsis occurred after trauma is significantly higher than that in patients without sepsis. By detecting the level of plasma or serum VNN1, early prediction of the sepsis occurrence risk of severely traumatized patients is performed, so as to give individualized intervention, thereby being capable of reducing the occurrence rate of post-traumatic sepsis, and having an importantclinical application value in improving the prognosis of patients with severe trauma.

ClotFoam is a sealant and hemostatic agent for use in cases of non-compressible hemorrhage for moderate to severe bleeding. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and/or a spray injection method following intracavitary severe trauma or surgery. Its crosslinking technology generates an adhesive scaffold that carries a fibrin sealant required for hemostasis. Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The composition is biocompatible and non-inflammatory.

The invention uses fibrin monomer polymerized by a change of pH as active sealing component. The viscoelastic properties of the foam as well as the rapid formation of a fibrin clot ensure that the sealant remains at the site of application without being washed away by blood.

The invention relates to the technical field of biology, in particular to application of an early response gene 3 (IER3) as a biomarker in a reagent or a kit for early prediction of sepsis. The IER3 is adopted as a biomarker, and crowd experiments prove that the IER3 level of plasma of a patient suffering from severe trauma sepsis is remarkably higher than that of a patient without sepsis. By detecting the plasma IER3 level, early prediction is conducted on the sepsis occurrence risk of a severely wounded patient so as to give individualized interventional therapy, the occurrence rate of post-traumatic sepsis can be reduced, and the important clinical application value can be achieved for improving prognosis of the severely wounded patient.

The invention relates to Uygur medicine composition, in particular to Uygur medicine calculus removing powder capable of treating urinary calculus and a preparation method thereof. Urinary calculus comprising kidney, ureter, urinary bladder and gallstone is a common disease. At present, the diseases are generally treated with traditional Chinese medicines, Chinese patent medicines, western medicines, calculus breakage and surgery treatment, and the curative effects of these medicines are not ideal; calculus breaking has poor or even ineffective treatment effects during treatment of calculus larger than 1 cm; the surgery treatment causes severe trauma to human bodies Raw material components of the powder comprise scorpion ash, tribulus terrestris, cucumber seeds, plegiocidaris pome, salt, semen cuscutae, mint, celery seeds, fennel, cichorium intybus and white granulated sugar. Uygur medical knowledge is adopted to distinguish diseases and symptoms, calculus dissolution and removal are integrated, and the curative effect is obviously superior to that of other proved recipes; the powder is economical, cheap, efficient, simple, practical, safe, non-toxic and acceptable among patients and is a relatively effective Uygur medicine for treating urinary calculus diseases at present.

The seepage drainage system comprises a nursing bed, a supporting bottom frame, a moving assembly, an adjusting assembly, a lifting assembly, a drainage assembly and a collecting assembly, the bottom of the moving assembly is welded to the top of the supporting bottom frame, and the front-back position of the drainage assembly is conveniently adjusted through the moving assembly; secondly, through cooperation with the adjusting assembly at the top of the moving assembly, the left-right position of the drainage assembly is adjusted through the adjusting assembly, and the drainage assembly can be conveniently used for conducting permeation drainage on the front and back different positions of the body of a patient on the nursing bed, so that the use flexibility of the permeation drainage system is improved; the permeable drainage system is simple in structure and convenient to use, the drainage assembly can conduct memory permeable drainage on the left and right trauma parts of the body of the patient, the movement area of the drainage assembly is wider, it is guaranteed that the permeable drainage system can conduct permeable drainage on different positions of the trauma parts of the patient, and the permeable drainage system can conduct permeable drainage on the trauma parts of the patient more comprehensively.

Kappa-opioid agonists prevent the impairment of renal function otherwise caused by the combination of gaseous anesthesia and surgery or severe trauma. Not only do these agents preserve renal function and maintain urine output, they also maintain plasma electrolyte concentration and osmolality by reducing renal loss of sodium and potassium when compared to other diuretic agents. The preservation of urine flow as well as the ability to retain body sodium, potassium, calcium, and osmolality during surgery or severe trauma under gaseous anesthesia are novel and unique properties associated only with kappa opioid agonists. To date, no other clinically-used diuretic agent has been shown to provide constant urine flow, or to retain electrolytes during anesthesia and surgery. The kappa opioid agonists may be used in surgical patients with normal cardiovascular function, but are particularly useful in patients with compromised cardiovascular and/or renal function. Continuous intravenous infusion of the kappa agonist preferably begins about 30 to 90 minutes before induction of anesthesia, and continues throughout anesthesia and surgery. The result is a constant and adequate output of urine while maintaining homeostasis of blood volume, electrolyte concentration, and osmolality throughout surgery and anesthesia. The dose of the kappa opioid agonist needed to induce diuresis during anesthesia is significantly higher than the dose needed to induce diuresis in a conscious patient.